| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| H130206-1mg |
1mg |
现货  |
|
| 别名 | 24-脱氢胆固醇 | 5,24-胆甾二烯-3β-ol | 去氢胆甾醇 |
|---|---|
| 英文别名 | 110798 | AVSXSVCZWQODGV-DPAQBDIFSA-N | F87896 | NSC-226126 | NSC 226126 | 24-Dehydrocholesterol | cholest-5,24-dien-3beta-ol | DESMOSTEROL | SCHEMBL156561 | (3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-[(2R)-6-methylhept-5-en-2-yl]-2,3,4,7,8,9,11,12,14,15 |
| 规格或纯度 | Moligand™, ≥99% |
| 英文名称 | 3β-hydroxy-5,24-cholestadiene |
| 生化机理 | 链甾醇是Bloch途径中的胆固醇前体，24-去氢胆固醇还原酶在此步骤中起催化作用。链甾醇在24-去氢胆固醇还原酶的损耗过程中累积，导致链甾醇化。链甾醇是肝X受体(LXR)激动剂。它是治疗神经退行性疾病的潜在靶点。链甾醇可调节巨噬细胞中的炎症信号。 |
| 储存温度 | -20°C储存 |
| 运输条件 | 超低温冰袋运输 |
| 产品介绍 |
与胆固醇相比，链甾醇缺少C24和C25之间的双键。它存在于精细胞和星形胶质细胞的细胞膜中，也是大脑主要固醇。 应用： |
| 活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| 活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|
| EC号 | 206-236-2 |
|---|---|
| 分子类型 | 小分子 |
| IUPAC Name | (3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-[(2R)-6-methylhept-5-en-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol |
| INCHI | InChI=1S/C27H44O/c1-18(2)7-6-8-19(3)23-11-12-24-22-10-9-20-17-21(28)13-15-26(20,4)25(22)14-16-27(23,24)5/h7,9,19,21-25,28H,6,8,10-17H2,1-5H3/t19-,21+,22+,23-,24+,25+,26+,27-/m1/s1 |
| InChi Key | AVSXSVCZWQODGV-DPAQBDIFSA-N |
| Canonical SMILES | CC(CCC=C(C)C)C1CCC2C1(CCC3C2CC=C4C3(CCC(C4)O)C)C |
| Isomeric SMILES | C[C@H](CCC=C(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C |
| PubChem CID | 439577 |
| 分子量 | 384.64 |
| 分子量 | 384.600 g/mol |
|---|---|
| XLogP3 | 8.300 |
| 氢键供体数Hydrogen Bond Donor Count | 1 |
| 氢键受体数Hydrogen Bond Acceptor Count | 1 |
| 可旋转键计数Rotatable Bond Count | 4 |
| 精确质量Exact Mass | 384.339 Da |
| 单同位素质量Monoisotopic Mass | 384.339 Da |
| 拓扑极表面积Topological Polar Surface Area | 20.200 Ų |
| 重原子数Heavy Atom Count | 28 |
| 形式电荷Formal Charge | 0 |
| 复杂度Complexity | 641.000 |
| 同位素原子数Isotope Atom Count | 0 |
| 定义的原子立体中心计数Defined Atom Stereocenter Count | 8 |
| 未定义的原子立体中心计数Undefined Atom Stereocenter Count | 0 |
| 定义的键立体中心计数Defined Bond Stereocenter Count | 0 |
| 未定义的键立体中心计数Undefined Bond Stereocenter Count | 0 |
| 所有立体化学键的总数The total count of all stereochemical bonds | 0 |
| 共价键合单元计数Covalently-Bonded Unit Count | 1 |
| Purity(GC) | 99-100（%） |
|---|---|
| Appearance（H130206) | White powder |
| Infrared spectrum | Conforms to Structure |
| Solubility in CHCL3，Colorless,Clear,20 mg/mL | pass |
| 1. Xu Xing, Chen Jun, Li Yan, Yang Xiaojie, Wang Qing, Wen Yanjun, Yan Ming, Zhang Jianjun, Xu Qin, Wei Yan, Chen Wantao, Wang Xu. (2021) Targeting epigenetic modulation of cholesterol synthesis as a therapeutic strategy for head and neck squamous cell carcinoma. Cell Death & Disease, 12 (5): (1-15). [PMID:33986254] [10.1038/s41419-021-03760-2] |
| 1. Xu Xing, Chen Jun, Li Yan, Yang Xiaojie, Wang Qing, Wen Yanjun, Yan Ming, Zhang Jianjun, Xu Qin, Wei Yan, Chen Wantao, Wang Xu. (2021) Targeting epigenetic modulation of cholesterol synthesis as a therapeutic strategy for head and neck squamous cell carcinoma. Cell Death & Disease, 12 (5): (1-15). [PMID:33986254] [10.1038/s41419-021-03760-2] |
首页
400-620-6333
C2226710